• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Interleukin Genetics Inc.

Smiths’ H1 sales rise 7 percent | Earnings roundup

March 24, 2011 By MassDevice staff Leave a Comment

MassDevice.com Earnings Roundup

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: Bioject Medical Technologies Inc., Cambridge Heart Inc., Datatrak International Inc., Instrumentation Laboratory, Interleukin Genetics Inc., Neogen Corp., Q4, Smiths Group plc

Earnings roundup: Cardica surges to Q1 profits

November 12, 2010 By MassDevice staff Leave a Comment

MassDevice.com Earnings Roundup

Cardica surges to Q1 profits
Cardica Inc. (NSDQ:CRDC) posted profits of $6.2 million, or 25 cents per share, on sales of $10.0 million during the three months ended Sept. 30. That compares with losses of $2.7 million, or 17 cents per diluted share, on sales of $947,000 during the same period last year.

Filed Under: Business/Financial News, MassDevice Earnings Roundup, News Well Tagged With: American Bio Medica Corp., CAS Medical Systems Inc., Corgenix Medical Corp., Datatrack International Inc., dextera, Dynatronics Corp, Guided Therapeutics Inc., Interleukin Genetics Inc., Vermillion Inc., VirtualScopics Inc.

Interleukin goes pink

August 16, 2010 By MassDevice staff Leave a Comment

ILIU logo

Interleukin Genetics Inc. (OTC:ILIU) is no longer traded on the New York Stock Exchange, effective today.

The company transferred its common stock to the OTC:QB marketplace, a new tier of the Pink OTC Markets created in April to better distinguish securities that remain compliant with regulatory reporting requirements but do not meet listing criteria for other exchanges. The company’s ticker symbol, formerly ILI, is now ILIU.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Interleukin Genetics Inc.

Interleukin Genetics doubles revenues, trims Q2 net loss

August 13, 2010 By MassDevice staff Leave a Comment

ILI logo

Interleukin Genetics Inc. (AMEX:ILI) may be proving that going to the right college can get you ahead in life.

The Waltham, Mass.-based company more than doubled year-over-year revenue comparisons and cut its quarterly loss by more than half, posting a $1.4 million net loss on $573,000 in revenues during the three months ended June 30. Interleukin also beat analysts’ expectations with both its top- and bottom-line results.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, MassDevice Earnings Roundup, News Well Tagged With: Interleukin Genetics Inc.

UMich to evaluate Interleukin’s genetic test for periodontal disease

August 12, 2010 By MassDevice staff

ILI logo

The University of Michigan embarked on a study of Interleukin Genetics Inc.’s (NYSE:ILI) genetic test for severe periodontal disease.

The Waltham, Mass.-based company contracted the university’s School of Dentistry to conduct research using a dental claims database to discern whether risk factors, such as genetic information, can guide more successful intervention and so reduce the effects of periodontal disease, such as tooth loss, according to a press release.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Interleukin Genetics Inc.

NYSE warns Interleukin of possible de-listing

June 28, 2010 By MassDevice staff Leave a Comment

ILI logo

The New York Stock Exchange warned Interleukin Genetics Inc. (NYSE:ILI) that it faces de-listing from the exchange for running afoul of its equity and profitability requirements.

The Waltham, Mass.-based genetic test maker said it received a letter June 24 from NYSE regulators informing it that “the Exchange intends to initiate proceedings to delist the Company’s common stock” for posting stockholders’ equity of less than $6 million and losses from continuing operations and/or net losses in its five most recent fiscal years.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Interleukin Genetics Inc.

Interleukin adds VC vet to board

April 30, 2010 By MassDevice staff Leave a Comment

ILI logo

Interleukin Genetics Inc. (NYSE:ILI) named a venture capital veteran, William Mills III, to its board of directors.

Mills will replace the Waltham, Mass.-based company’s founder, president and chief scientific officer Ken Kornman if shareholders approve his election at the company’s annual meeting June 17. His resumé includes stints at The Venture Capital Fund of New England, PaineWebber Ventures/Ampersand Ventures, EGS Healthcare Capital Partners, Advent International and Ascension Health Ventures, where he’s a member of the board of managers.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Interleukin Genetics Inc.

Interleukin raises $5 million

March 5, 2010 By MassDevice staff Leave a Comment

Interleukin Genetics Inc. (NYSE:ILI) drummed up about $5.3 million in commitments from institutional investors in a registered direct offering.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Interleukin Genetics Inc.

Interleukin named in patent suit by Australian genetic testing firm

March 2, 2010 By MassDevice staff Leave a Comment

Interleukin Genetics Inc. (NYSE:ILI) and seven other firms were named in a patent infringement lawsuit filed by an Australian genetic testing company.

Genetic Technologies Ltd. of Victoria, Australia, asserts that Interleukin is one of eight companies violating a patent it holds for “Intron Sequence Analysis Method for Detection of Adjacent Locus Alleles as Haplotypes,” according to documents filed in the U.S. District Court for Western Wisconsin.

Beckman Coulter Inc. (NYSE:BEC) was also named in the suit, which alleges that each of the companies developed products that infringe on one or more claims held in U.S. Patent No. 5,612,179, which Genetic Technologies was granted in May 1997.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Interleukin Genetics Inc.

Interleukin Genetics heart attack test hits the market in Europe

January 19, 2010 By MassDevice staff Leave a Comment

Labec Pharma S.L. met European regulatory guidelines to sell a test made by Interleukin Genetics Inc. (NYSE:ILI) designed to predict the risk of heart attack.

Waltham, Mass.-based Interleukin said its Heart Health genetic test will be marketed to physicians in Spain and Portugal under the Cardio Health brand. Samples will be processed at Interleukin’s lab in Waltham and the company will receive royalties and processing fees for each test sold by Madrid-based Labec.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Interleukin Genetics Inc.

Interleukin Genetics plans offering for up to $75 million in new funds

January 6, 2010 By MassDevice staff Leave a Comment

Expect to see Interleukin Genetics Inc. (NYSE:ILI) on the hunt for additional money in coming months, after it signaled plans Jan. 6 to sell up to $75 million in new securities.

The preliminary prospectus does not commit the Waltham, Mass.-based genetic test maker to a specific timetable for the proposed securities offerings and also does not indicate how company officials would spend proceeds from any of those sales.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Interleukin Genetics Inc.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy